Regeneron’s Eylea (aflibercept) Achieves 1EP & 2EP in P-III PANORAMA trial in Patients with Non-Proliferative Diabetic Retinopathy (NPDR)

 Regeneron’s Eylea (aflibercept) Achieves 1EP & 2EP in P-III PANORAMA trial in Patients with Non-Proliferative Diabetic Retinopathy (NPDR)

Regeneron’s Eylea (aflibercept) Achieves 1EP & 2EP in P-III PANORAMA trial in Patients with Non-Proliferative Diabetic Retinopathy (NPDR)

Shots:

  • The P-III PANORAMA trial involves assessing of Eylea (q8w, q16w) vs PBO (sham injection) in 402 patients with moderately-severe and severe NPDR for 52 weeks
  • P-III PANORAMA trial results: Development of VTCs (3%, 4% vs 20%); CI-DME occurrence (8%, 7% vs 26%); Collective occurrence of VTC & CI-DME (11%, 10% vs 41%). The avg. no.of IV @8wks  &16 wks. are (8.9 & 5.5) respectively
  • Eylea IV a prefilled syringe is a VEGF inhibitor formulated for eye. Regeneron has submitted its sBLA in diabetic retinopathy based on 24 wks. results under the US FDA with PDUFA date 13 May, 2019

Click here to read full press release/ article | Ref: Regeneron | Image: Eylea

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post